The success of toll-like receptor 4 based vaccine adjuvants
Open Access
Abstract
No abstract availableKeywords
This publication has 112 references indexed in Scilit:
- Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue SarcomaJAMA Oncology, 2023
- TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signalingCellular and Molecular Life Sciences, 2020
- First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1Cancer Immunology, Immunotherapy, 2019
- Below the surface: The inner lives of TLR4 and TLR9Journal of Leukocyte Biology, 2019
- Development of the CpG Adjuvant 1018: A Case Study2016
- Non‐clinical safety and biodistribution of AS03‐adjuvanted inactivated pandemic influenza vaccinesJournal of Applied Toxicology, 2015
- Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL‐18, and IFN‐γEuropean Journal of Immunology, 2014
- MyD88 and TRIF synergistic interaction is required for TH1‐cell polarization with a synthetic TLR4 agonist adjuvantEuropean Journal of Immunology, 2013
- Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix®Advances in Therapy, 2009
- Liposomes containing lipid A: A potent nontoxic adjuvant for a human malaria sporozoite vaccineImmunology Letters, 1990